The company is responsible for developing a new diagnostic method for chronic obstructive pulmonary disease (COPD), a respiratory disease that hampers air from entering the lungs. Antoni Rosell, Clinical Director of the Thorax Department of the Germans Trias Hospital, is mover of the project.
"We want to make sure that the medical and nursing staff as well as patients have the tools necessary for a timely and precise diagnosis of chronic respiratory diseases in environments with limited resources, as Primary Care" explains Petra Stockinger CSO and co-leader, together with Hugall, of this project. "We want to reduce the huge burden of this disease for the society and the health system, improving the quality of life of patients, and decreasing mortality and hospitalizations". The project also counts on the collaboration of the chief mechanical engineer Rodolfo Plaza Herz.
The device prototype that is been developed for diagnosing respiratory diseases is fast (less than 5 minutes), offers precise and easy-to-interpret results, and requires little training. In this way, it allows detecting and diagnosing diseases timely in all clinical environments, especially in Primary Care, which is an area that needs a timely detection. Although its first focus is on COPD, the platform will be eventually extended to other respiratory diseases.
In 2020, they decided to create Breaz Medical SL, with the objective to develop and commercialize a new solution for the diagnosis of lung diseases. During this last year, they have strengthened their commitment and association with IGTP, where the project was born, and with the Germans Trias Hospital, both CataloniaBIo & HealthTech members, which will permit completing the development of the project and perform clinical tests. They have been selected to participate in prestigious start-up national and international programs such as the EIT Health MedTech Bootcamp or the StartHealth. Recently, they have received 'Impact Business' award of the Ship2B Foundation.
Breaz joins the 7 spin-offs that belong to the IGTP team: Biointaxis, Ahead Therapeutics, Aniling, Innovex Therapeutics, Time is Brain, Manremyc, and Nimble.
Photo: Antoni Rosell (Hospital Germans Trias), James Hugall (Breaz Medical), Petra Stockinger (Breaz Medical) and Jordi Barretina (IGTP)
Comments